From vaccine production to molecular biology to industrial engineering Ziccum’s Board members bring extensive expertise to the company and its business and technology development.
Fredrik Sjövall, Chairman
Appointed: April 5, 2017.
Qualifications: M.Sc. Automation Engineering, Master’s Degree in Business Development. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Fredrik has got 20 years of experience from management positions in the life science industry. Previously the CEO of Inhalation Sciences, Hemcheck, Lipopeptide and PharmaSurgics.
Current roles: Currently Chairman at the public companies Lipidor and Monivent. Also Chairman of Emollivet and board member of Phargentis.
Ownership: 158 000 shares and 42 200 warrants
Appointed: 20 Maj 2019.
Qualifications: MSc Molecular Biology. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Mikaela has 20 years of experience working at major global life-science companies. She has held several strategic commercial roles and senior management positions in the Nordic region, on global and HQ level. During 1999-2008, various commercial roles with MSD Sweden AB, 2008-2012 local marketing and strategic roles with AstraZeneca Sweden and Nordic-Baltic. From 2012 to 2015 she was the Global Head of Astra Zeneca’s Vaccine Franchise, from 2015-2019 Vice President of Nordic-Baltic Business Unit in Respiratory, Inflammation and Autoimmune disease (RIA). Since Aug 2019 Head of Nordic Region for Real World Evidence at IQVIA.
Ownership: 9 000 shares and 42 200 warrants
Andreas Pettersson Rohman
Appointed: April 27 2021.
Qualifications: MSc. and BSc. Industrial Engineering and Management, Chalmers University of Technology. MSc. Advanced Finance, School of Business, Economics and Law, Gothenburg University. BSc National Economics, School of Business, Economics and Law, Gothenburg University.
Experience: Andreas has extensive experience from strategy development as well as supportive debt and equity financing. He currently serves as Vice President Corporate Finance and Investor Relations at Northvolt and previously worked as an Investment Professional at EQT within the Private Equity business line and prior to that at Goldman Sachs International in London within the Investment Banking Division.
Ownership: 39 333 shares and 42 200 warrants
Appointed: May 24, 2023
Qualifications: Associate Professor of Inhalation Toxicology, Scientist at the Division of Physiology, Institute of Environmental Medicine at the Karolinska Institutet and founder of the Company. Previous appointments include scientist at the Lovelace Respiratory Research Institute (1993– 1998), scientist at the Swedish National Institute of Occupational Health (1991–1996), and postdoctoral fellow at the Lovelace Respiratory Research Institute (1989–1991). Gerde has published approx. 55 peer reviewed scientific papers. He is also the main inventor of six patent families with related patent applications.
Current roles: CSO and Board member in Inhalation Sciences Sweden AB
Ownership: 220 000 shares